Infiltrating ASCs from perioprostatic WAT have also been shown to play a role in obesity driven systemic therapy resistance and prostate cancer progression via production of CXCL12 and other chemokines (90–92, 106). This evidence concerns the gene CXCL12 and prostate carcinoma.